Hot Features
Premium
Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
Period:
Draw Mode:
| Volume | 65,777 |
|
|||||
| News | - | ||||||
| Day High | 2.65 | Low High |
|||||
| Day Low | 2.3801 | ||||||
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Aditxt Inc | ADTX | NASDAQ | Common Stock |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| -0.14 | -5.53% | 2.39 | 18:48:29 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 2.46 | 2.3801 | 2.65 | 2.39 | 2.53 |
| Trades | Shares Traded | VWAP | Financial Volume | Average Volume | 52 Week Range |
|---|---|---|---|---|---|
| 581 | 65,777 | US$ 2.48 | US$ 163,182 | - | 2.14 - 68.08 |
| Last Trade | Type | Quantity | Price | Currency |
|---|---|---|---|---|
| 18:57:26 | formt | 200 | US$ 2.39 | USD |
Aditxt Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 4M | 1.67M | - | 934k | -27.65M | -16.60 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Aditxt News
| Date | Time | Source | News Article |
|---|---|---|---|
| 4/02/2024 | 07:30 | Business Wire | Aditxt Signs a Definitive Agreement to Acquire Appili.. |
| 3/27/2024 | 07:36 | PR Newswire (US) | Evofem Reports $18.2 million of Phexxi Net Product Sales in.. |
| 3/11/2024 | 15:51 | Edgar (US Regulatory) | Form 8-K - Current report |
| 3/07/2024 | 06:54 | PR Newswire (US) | For Women Using GLP-1 Receptor Agonists who take Oral Birth.. |
| 3/04/2024 | 16:27 | Edgar (US Regulatory) | Form 425 - Prospectuses and communications, business.. |
| 3/04/2024 | 16:24 | Edgar (US Regulatory) | Form 8-K - Current report |
| 3/01/2024 | 15:01 | Edgar (US Regulatory) | Form 8-K - Current report |
| 2/29/2024 | 15:01 | Edgar (US Regulatory) | Form 8-K - Current report |
| 2/22/2024 | 16:21 | Edgar (US Regulatory) | Form 8-K/A - Current report: [Amend] |
| 2/21/2024 | 15:30 | Edgar (US Regulatory) | Form 8-K - Current report |
| 2/16/2024 | 15:30 | Edgar (US Regulatory) | Form 8-K - Current report |
| 2/15/2024 | 15:30 | Edgar (US Regulatory) | Form 8-K - Current report |
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical ADTX Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 2.48 | 2.69 | 2.14 | 2.42 | 62,363 | -0.09 | -3.63% |
| 1 Month | 3.38 | 5.09 | 2.14 | 3.30 | 812,026 | -0.99 | -29.29% |
| 3 Months | 3.74 | 5.09 | 2.14 | 3.39 | 331,153 | -1.35 | -36.10% |
| 6 Months | 7.70 | 9.50 | 2.14 | 5.41 | 832,337 | -5.31 | -68.96% |
| 1 Year | 27.60 | 68.08 | 2.14 | 10.28 | 592,591 | -25.21 | -91.34% |
| 3 Years | 105.60 | 1,139.60 | 2.14 | 49.05 | 2,264,397 | -103.21 | -97.74% |
| 5 Years | 211.20 | 1,139.60 | 2.14 | 72.66 | 2,209,902 | -208.81 | -98.87% |
Aditxt Description
| Aditxt Inc is a life sciences company which focuses on prolong life and enhance life quality of transplanted patients. The firm develop products designed to induce tolerance to transplanted organs. The firm's immunosuppressive (anti-rejection) drugs has made possible life-saving organ transplantation procedures as these drugs prevent or delay organ rejection. It is also developing a technology called Apoptotic DNA Immunotherapy (ADi) which utilizes tolerogenic approach that utilizes the body's natural process of cell death, to deliver a modified antigen that signals the immune system to become tolerant to transplanted tissues. |
